Toth Financial Advisory Corp Sells 4,890 Shares of Ascendis Pharma A/S $ASND

Toth Financial Advisory Corp lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 91.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 445 shares of the biotechnology company’s stock after selling 4,890 shares during the period. Toth Financial Advisory Corp’s holdings in Ascendis Pharma A/S were worth $77,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Aristeia Capital L.L.C. raised its position in Ascendis Pharma A/S by 4.6% in the 1st quarter. Aristeia Capital L.L.C. now owns 11,300 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 500 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Ascendis Pharma A/S by 10.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock valued at $91,269,000 after acquiring an additional 55,164 shares during the last quarter. Cinctive Capital Management LP bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at $1,191,000. Advisors Asset Management Inc. raised its position in shares of Ascendis Pharma A/S by 11.5% during the 1st quarter. Advisors Asset Management Inc. now owns 9,190 shares of the biotechnology company’s stock valued at $1,432,000 after acquiring an additional 949 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at $51,029,000.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $197.68 on Monday. The firm has a 50-day moving average of $187.70 and a 200-day moving average of $171.27. The company has a market cap of $12.18 billion, a price-to-earnings ratio of -38.31 and a beta of 0.39. Ascendis Pharma A/S has a one year low of $118.03 and a one year high of $208.16.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have commented on ASND shares. Bank of America upped their target price on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Cowen reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a research report on Thursday, July 3rd. They set an “overweight” rating and a $250.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an “overweight” rating in a report on Tuesday, August 19th. Fifteen investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $244.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.